Search Results

Formoterol fumarate 100 mg  | 100.00%

TargetMol

Formoterol fumarate (Eformoterol Hemifumarate), an effective, specific and long-acting β2-adrenoceptor agonist, is utilized in the treatment of chronic obstructive pulmonary disease(COPD) and asthma.

More Information Supplier Page

HC-030031 50 mg  | 98.00%

TargetMol

HC-030031 (TOSLAB 829227) is a potent TRPA1 inhibitor, which antagonizes AITC- and formalin-evoked calcium influx with IC50s of 6.2±0.2 and 5.3±0.2 μM, respectively.

More Information Supplier Page

Halobetasol propionate 100 mg  | 99.85%

TargetMol

Halobetasol propionate (BMY-30056) is the propionate salt form of halobetasol, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictor activities. Halobetasol, a topical steroid, diffuses across cell membranes to interact with cytoplasmic corticosteroid receptors located in both the dermal and intradermal cells, thereby activating gene expression of anti-inflammatory proteins mediated via corticosteroid receptor response element. Specifically, […]

More Information Supplier Page

Halobetasol propionate 25 mg  | 99.85%

TargetMol

Halobetasol propionate (BMY-30056) is the propionate salt form of halobetasol, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictor activities. Halobetasol, a topical steroid, diffuses across cell membranes to interact with cytoplasmic corticosteroid receptors located in both the dermal and intradermal cells, thereby activating gene expression of anti-inflammatory proteins mediated via corticosteroid receptor response element. Specifically, […]

More Information Supplier Page

Formoterol fumarate 200 mg  | 100.00%

TargetMol

Formoterol fumarate (Eformoterol Hemifumarate), an effective, specific and long-acting β2-adrenoceptor agonist, is utilized in the treatment of chronic obstructive pulmonary disease(COPD) and asthma.

More Information Supplier Page

Copanlisib 25 mg  | 99.88%

TargetMol

Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor […]

More Information Supplier Page